At baseline patients treated with esketamine have higher burden of disease than other patients with treatment resistant depression: Learnings from a population based study.

Abstract

IntroductionIt is critical to assess who is being treated with a new marketed drug like esketamine to understand how it is used in the real‐world setting and the effects of the medication.MethodsRetrospective analysis using two large U.S. health care databases that included commercially insured and Medicaid patients. Patients treated with esketamine were identified and their baseline characteristics described and compared with the baseline characteristics of patients with treatment resistant depression (TRD) and with patients undergoing transcranial magnetic stimulation (TMS). To quantify the differences, standardized mean differences were calculated.ResultsIn the commercially insured database, 418 patients were treated with esketamine and 830,047 patients were in the TRD group. Large differences in baseline characteristics were observed. Patients in the esketamine group were more likely to have severe depression, suicidal thoughts, and prior treatments with TMS or electroconvulsive therapy than the TRD control group. Patients in the esketamine group had more comorbid psychiatric conditions (anxiety disorder, posttraumatic stress disorders, substance use disorders) and higher exposure to antipsychotics, antiepileptics, hypnotics and sedatives. In terms of general health, patients in the esketamine group had many more outpatient visits, were more likely to have chronic pain and higher Charlson comorbidity scores, a predicator of mortality. Results were similar for both the Medicaid and TMS populations.ConclusionPatients treated with esketamine have a higher burden of disease than other patients with TRD. In any real‐world comparative effectiveness or safety study these differences need to be understood and accounted for to produce valid results.